In 2026, Merck's stock surged 44% year-to-date, outperforming major U.S. drugmakers Amgen (up 35%) and Pfizer (up 14%). Merck's success is driven by its strong oncology portfolio, including the top-selling cancer drug KEYTRUDA, and diverse products beyond obesity drugs, which dominate the sector this year. Amgen holds second place with a broad product lineup and a promising obesity drug in late-stage development. Pfizer trails but remains attractive for income investors due to its 6.3% dividend yield. Investors should watch upcoming pipeline data and regulatory decisions, as the obesity drug race continues to shape the pharmaceutical landscape.
Bio-Techne reported Q4 revenues of $321.2 million, slightly surpassing estimates, but its adjusted EPS fell 1.9% year-over-year to $0.52, showing mixed financial results. The company's stock remains close to Merck KGaA's $73 per share acquisition off...
Moderna's stock surged over 125% in one week, driven by positive interim results from its Phase 3 trial of a personalized mRNA cancer vaccine for high-risk melanoma patients. The trial, conducted with partner Merck, showed success without new safety ...
Merck & Co. surged to all-time highs following positive Phase 3 trial results of its melanoma vaccine developed with Moderna. The company maintains a Buy rating due to strong growth in oncology, solid free cash flow, and potential for further stock g...
Merck & Co. shares have surged 72% since the last bullish call, outperforming the benchmark's 15% gain. Despite strong performance, the stock now trades at a high forward P/E ratio of 14x for 15 months ahead, with elevated earnings expectations for F...
Eli Lilly shows strong performance with 48% revenue growth driven by GLP-1 drugs Mounjaro and Zepbound, raising 2026 guidance significantly. Novo Nordisk struggles with pricing cuts and pipeline setbacks, keeping its stock range-bound despite solid s...
